GSK said on Friday a panel of the European Medicines Agency had backed the use of its respiratory syncytial virus (RSV) ...
The recommendation by the CHMP should now result in approval of Arexvy in the broader age range in February next year, and ...
In the third quarter, our revenue were $1 billion, driven by sales of our fully approved vaccines, Spikevax, mNEXSPIKE, ...
In a new study, adults 45 and up who got this seasonal virus had a higher risk of major heart issues, especially in the first ...
Last month marked a major turning point as Google launched Gemini 3 [1], proving that new AI models can now outperform humans on critical tasks. At the same time, global regulators accelerated the ...
Annual Meeting 2025 Highlights" report has been added to ResearchAndMarkets.com's offering. IDWeek is the joint annual meeting of the Infectious Diseases Society of America, the Society for Healthcare ...
Research led by the Veterans Affairs Portland Health Care System in Portland, Oregon, found that a single dose of respiratory ...
Emerging market opportunities include advanced therapies for RSV, COVID-19, UTIs, HIV, and fungal infections, with promising candidates such as Moderna's mRNA assets, GSK's TBP-PI-HBr, and Armata's AP ...
An RSV vaccination, RSVpreF vaccine (Abrysvo), is recommended for use during pregnancy (maternal RSV vaccine). It is given during RSV season to people who are 32 through 36 weeks and 6 days pregnant.
Moderna secured a $1.5 billion loan from Ares Management, structured in three tranches, to support financial flexibility and ...
Targets readouts from nine ongoing Phase 2 and Phase 3 clinical studies in its oncology pipeline, including three Phase 3 programs for intismeran autogene Further improves 2026 and 2027 expected GAAP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback